|
T10096L |
Voruciclib
|
|
CDK
|
|
Voruciclib is an orally active and selective CDK inhibitor (Ki: 0.626 nM-9.1 nM). Voruciclib represses the expression of MCL-1 in multiple models of diffuse large B-cell lymphoma. Voruciclib effectively blocks CDK9, the ... |
|
T16040 |
Mepazine
|
Pecazine |
Apoptosis
,
MALT
|
|
Mepazine (Pecazine) is a potent and selective inhibitor of MALT1. Mepazine inhibits GSTMALT1 full length and GSTMALT1 325-760 with IC50s of 0.83 μM and 0.42 μM. Mepazine enhances apoptosis and affects the cell viability. |
|
T5354 |
IRAK4-IN-7
|
CA-4948 |
IRAK
|
|
IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model. |
|
T14367 |
AZ1495
|
|
IRAK
,
CDK
,
Haspin Kinase
|
|
AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Which Shows activity in treatment of mutant MYD88L265P diffu... |
|
T3549 |
Avadomide
|
CC 122 |
Apoptosis
,
E1/E2/E3 Enzyme
,
Ligand for E3 Ligase
|
|
Avadomide (CC 122) is an orally available pleiotropic pathway modulator with potential antineoplastic activity. |
|
T77367 |
Urelumab
|
BMS-663513,BMS-66513 |
Others
|
|
Urelumab(BMS-66513) is a humanized IgG4 monoclonal antibody, often used as a CD137 agonist.Urelumab has potential antitumor activity, potentiating tumor cell killing by T-cells and natural killer cells, and enhancing the... |
|
T77940 |
Tazemetostat de(methyl morpholine)-COOH
|
|
Ligands for Target Protein for PROTAC
|
|
Tazemetostat de(methyl morpholine)-COOH (compound 7), a PROTAC ligand for EZH2, facilitates the synthesis of PROTACs that target this enzyme. These EZH2 degraders exhibit potent inhibition of cell viability in diffuse la... |
|
T73869 |
BCL6 PROTAC 1
|
|
|
|
BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) proteolysis targeting chimera (PROTAC) that inhibits the BCL6 cell reporter with an IC50 value of 8.8 µM and significantly degrades BCL6 in diffuse large B-cell lymph... |
|
T77070 |
Loncastuximab
|
|
|
|
Loncastuximab (RB4v1.2), an anti-CD19 monoclonal antibody, exhibits antitumor properties and holds potential for treating non-Hodgkin's lymphoma (NHL), specifically diffuse large B-cell lymphoma (DLBCL) [1] [2]. |
|
T79485 |
IRAK4-IN-27
|
|
IRAK
|
|
IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor, demonstrating an IC50 of 8.7 nM. It effectively suppresses cell growth and induces apoptosis in the MYD88 L265P diffuse large B-cell lymphoma (DLBCL) c... |
|
T81696 |
NBI-961
|
|
|
|
NBI-961, a potent NEK2 inhibitor, suppresses proteasomal degradation and effectively induces G2/mitosis arrest and apoptosis within diffuse large B cell lymphoma (DLBCL) cells [1]. |
|
T62403 |
DM-01
|
|
|
|
DM-01 is a potent and selective inhibitor of EZH2. DM-01 can be used to study diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and SNF5/INI-1/SMARCB1 gene-associated solid tumours. |
|
T26688 |
Avadomide HCl
|
Avadomide hydrochloride,CC122, Avadomide HCl,CC-122,CC 122 HCl |
|
|
Avadomide is an orally available pleiotropic pathway modulator with potential antineoplastic activity. CC-122 mimics an interferon response and has antitumor activity in DLBCL CC-122 binds Cereblon (CRBN) and promotes de... |
|
T79801 |
TCIP 1
|
|
Epigenetic Reader Domain
|
|
TCIP 1 is a small molecule in the category of transcriptional/epigenetic covalent inhibitor probes (TCIPs) that forms covalent bonds with molecules targeting BCL6 and BRD4. This compound facilitates cell death gene expre... |
